Enliven Therapeutics, Inc.ELVN
Price (close)
$44.75
Market cap
$3.3B
P/E
—
Revenue (TTM)
—
Net income
-$105.9M
Dividend yield
—
1-year total return
141.0%
Net margin
—
Revenue growth
—
Debt / equity
—
What Enliven Therapeutics, Inc. does.
No business description on file yet.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net income | -$41.4M | -$51.4M | -$37.7M | -$71.6M | -$89.0M | -$103.7M |
| Free cash flow | -$37.4M | -$46.8M | -$32.7M | -$61.4M | -$73.2M | -$70.5M |
More on ELVN.
- Enliven Therapeutics, Inc. summary
- Enliven Therapeutics, Inc. financial statements
- Enliven Therapeutics, Inc. key metrics
- Enliven Therapeutics, Inc. health scores and style box
- Enliven Therapeutics, Inc. earnings
- Enliven Therapeutics, Inc. dividends
- Enliven Therapeutics, Inc. valuation
- Enliven Therapeutics, Inc. ownership and insiders
- Enliven Therapeutics, Inc. peers
Figures from Enliven Therapeutics, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.